What is Axio Biosolutions Private?
Founded in 2008 and headquartered in Cambridge, Massachusetts, Axio Biosolutions Private is an ISO 13485 certified medical device company specializing in advanced wound care. Leveraging innovative biopolymer-based medical technology, Axio develops novel woundcare products. Its flagship offering, Axiostat, is a 100% chitosan haemostatic dressing designed to rapidly control severe hemorrhage by adhering to trauma wounds. This award-winning, CE-approved product is utilized by defense forces globally, highlighting its efficacy in critical care scenarios.
How much funding has Axio Biosolutions Private raised?
Axio Biosolutions Private has raised a total of $18.6M across 2 funding rounds:
Series B
$12.6M
Other Financing Round
$6M
Series B (2020): $12.6M with participation from Accel, Chiratae Ventures, University of California, and Omidyar Network India
Other Financing Round (2021): $6M led by TrueScale Capital, UC Ratan Tata Fund, Accel, and Omidyar Network India
Key Investors in Axio Biosolutions Private
Accel
Accel is a global venture capital firm that partners with exceptional teams from the inception of their ideas through all phases of private company growth. The firm focuses on supporting innovative companies and entrepreneurs. Accel aims to be the first partner for teams looking to scale and succeed in their respective markets. Their services are tailored to meet the needs of startups and growing businesses.
Omidyar Network India
Omidyar Network India invests in bold entrepreneurs who help create a meaningful life for every Indian, especially the hundreds of millions of Indians in low-income and lower-middle-income populations, ranging from the poorest among the company to the existing middle class. To drive empowerment and social impact at scale, the company works with entrepreneurs in the private, non-profit, and public sectors, who are tackling India's hardest and most chronic problems.
Chiratae Ventures
Chiratae Ventures is an established Indian technology venture capital fund advisor based in Bengaluru, managing $1.3 billion in assets across seven funds. The firm has a strong track record with over 130 investments, 56 exits, and eight unicorns, having returned approximately $900 million to its limited partners in the last 13 years.
What's next for Axio Biosolutions Private?
The recent major strategic investment signals a pivotal phase for Axio Biosolutions Private, likely enabling the company to accelerate product development, expand market reach, and further scale its operations. With a strong foundation in biopolymer technology and a proven product like Axiostat, this capital infusion is expected to drive innovation in advanced wound care solutions and solidify its position in both civilian and defense medical markets. Future growth may involve further clinical validation, international market penetration, and the development of next-generation wound management technologies.
See full Axio Biosolutions Private company page
